Phase 3 · NCT05882045
TRIUMPH-3
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
Registry record
Trial details
- Trial
- TRIUMPH-3
- ClinicalTrials.gov ID
- NCT05882045
- Indication
- Obesity, Cardiovascular Diseases
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 1,946
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 169 sites · Argentina, Australia, Canada, Hungary, Mexico, Poland, Puerto Rico, Slovakia, Spain, United States
- Study start
- 30 May 2023
- Primary completion
- 16 Apr 2026
- Study completion
- 14 May 2026
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 30 Jul 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Recruitment status | Recruiting→Completed | 4 Sept 2026 | ClinicalTrials.gov |
| Enrolment | 1200→1946 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary completion date | 2027-09-30→2026-04-16 | 4 Sept 2026 | ClinicalTrials.gov |
| Study completion date | Data pending→2026-05-14 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary endpoints | Data pending→Percent Change from Baseline in Body Weight | 4 Sept 2026 | ClinicalTrials.gov |